Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity hails growth prospects at Dunelm despite CEO exit

(Sharecast News) - The surprise retirement of Dunelm's boss shouldn't put off investors from the homeware retailer's strong growth prospects, according to Canaccord Genuity which reiterated its 'buy' rating on the stock. Nick Wilkinson announced on Tuesday that he would be stepping down from the company, choosing to retire from full-time executive life.

But while his departure creates some uncertainty for the business - the company is starting a thorough recruitment process and considering both internal and external candidates - analyst Mark Photiades from Canaccord Genuity isn't fazed.

"We continue to believe that Dunelm offers an attractive growth opportunity with significant share gain opportunities in under-penetrated categories coupled with further UK store expansion potential," Photiades said.

"The retirement of well-respected CEO Nick Wilkinson after nearly eight years, whilst not expected, should not detract from the group's long-term growth opportunity."

The news came alongside Dunelm's first-half results, which showed a "robust" performance, Photiades said, with continued market outperformance despite a challenging macro environment.

The analyst highlighted that the price-to-earnings ratio of 12.9x offers good value for a market leader with strong growth prospects.

The stock was trading 0.5% higher at 978p by 1203 GMT, with plenty of upside to Canaccord Genuity's 1,270p target price.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.